ROCKET STOCK: TECHTRAN POLYLENSES LTD (BSE Code : 523455) at 23/- Target 50/- & 135/-

STOCK : TECHTRAN POLYLENSES LTD Trading in BSE CODE : 523455.

Now It's Bio Pharma Company

Another NATCO Pharma (Recommend at 40/- now 435/-); Same like this Techtran also move to 500/- 1 to 3 years time.

CMP : 23/-

Target : 50/- to 135/- in Short term and Medium terms For Long Term will go 500/- Like Natco Pharma.

Equity : 14 Cr

Face Value : 10/-

Promoters Holding : 38%

Techtran Poly Takeover by Mr Jayaram Chigurupati who was the promoter of Zenotech Lab Ltd. And earlier was the managing director of a subsidiary of Dr Reddy's.

Jayaram is Merged his Multi National company Hemarus Locating India and USA with Techtran Poly. Hemarus is a specialty plasma derived biopharmaceuticals company. (http://hemarus.co.in/)

Profits For 2011-12

First Quarter Net Profit was 1.5 Cr

Second Quarter was 1.7 Cr

Third Quarter was 1 Cr

Fourth Quarter expecting 1.9 Cr

So Total EPS of 20011-12 nearly 5/- above.

Expecting EPS for 2012- 13 is 10/-

Expecting EPS for 2013-14 is 23/-

Based on this Share will go 135/- 350/- and 500/- in 2 to 3 years time.

Techtran Polylenses Ltd is engaged in the business of Manufacture & Sale of Hard Resin Plastic Ophthalmic Lenses. It is the largest producer of plastic lenses in India and is the only ISO 9002 certified, Ophthalmic lens manufacturing unit in the country, offering full range of lenses. The plant is located in Andhra Pradesh and the total capacity is about five million lenses per annum

Recently (1 year) Company Changed Management. Takeover by Big NRI has been acquired by Mr Jayaram Chigurupati who was the promoter of Zenotech Lab Ltd. Jayaram earlier was the managing director of a subsidiary of Dr Reddy's and he was largely responsible for establishing the presence of Dr Reddy's in a number of emerging markets. Thereafter he floated the Zenotech Lab and then he sold Zenotech Lab to Ranbaxy Ltd and he also sold his own personal stake in Zenotech Lab to Ranbaxy.He is focussing bigtime now on techtran poly and aims to make it a company to reckon for in the industry it operates in.

Jayaram is Merged his company Hemarus with Techtran Poly. Hemarus is a specialty plasma derived biopharmaceuticals company (http://hemarus.co.in/) committed to innovate, develop and commercialize high-quality plasma derivatives to save lives and enhance quality of life for people with bleeding disorders. Hemarus operates through an integrated platform of safe and reliable collection of high-quality human plasma, a state-of-the-art fractionation facility capable of producing life-saving therapies in conformance to most stringent international standards, supported by a cross functional team of scientists

Manufacturing Facilities :
Hemarus has set up a state-of-the-art US FDA approvable cGMP integrated Plasma fractionation facility of 36,000 square feet of infrastructure at Hyderabad with a capacity to process 120,000 litres of plasma annually

The facility is the first of its kind in India that has been designed to use a complete end-to-end chromatography based process for production of plasma derivatives. Currently the majority of the life-saving plasma product requirement in India is met through imports. High quality plasma derivatives manufactured in our facility shall bridge this gap besides also being marketed globally.

R & D
Keeping in view Hemarus's commitment to innovate for life, the R&D team continuously strives to develop processes to produce the highest quality products using most advanced state-of-the-art technologies in the field. Plasma derivatives are manufactured using end-to-end advanced chromatography based processes as opposed to the older technology using Cohn's precipitation techniques. Viral safety is ensured by the incorporation of multiple orthogonal viral inactivation and removal steps in the process. The plasma derivatives manufactured by Hemarus conforms or exceed the most stringent international standards for safety and efficacy of plasma derivatives.

Scientists at Hemarus are actively engaged in a wide variety of projects ranging from development of new plasma products, new formulations to identifying new targets for therapeutic intervention.

In this Market Correction Time Buy Good Fundamental and Multi Return Stocks Like Techtran Polylences Ltd and hold it will get good return No risk at all like this stocks.

Techtran Polylences Ltd having Lot Expansion Plans in Future. Its a Multibagger stock. Just buy and hold 1 year will get 10 times Return like NATCO Pharma Ltd (I have Recommended at 40/- Now 435/-) and SE Investment (This Stock I have Recommended at 175/- levels after that reached 1200/- levels including Bonus and Split).

Positive Points for this stock for Up moving:
1) Company focusing on business segments – Bio Pharma, Company Circle people. Mutual Funds and Operators are accumulating at current price. Because Company Stock Good Value to buy at 23/- Good Profit making company and Good Assets.